IDH1 and cancer: Immunostaining is accomplished with fluorescent antibodies against EV markers such as CD9, CD63, and CD81 or cancer markers, in this particular study from three glioblastoma cell lines overexpressing EGFRvIII, EGFR, or IDH1‐R132.